Application 050672
- Type
- NDA
- Sponsor
- GLAXOSMITHKLINE
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | CEFTIN | CEFUROXIME AXETIL | FOR SUSPENSION;ORAL | EQ 125MG BASE/5ML | Yes | No |
| 002 | CEFTIN | CEFUROXIME AXETIL | FOR SUSPENSION;ORAL | EQ 250MG BASE/5ML | Yes | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N050672-001 | CEFTIN | CEFUROXIME AXETIL | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1994-06-30 | |
| N050672-002 | CEFTIN | CEFUROXIME AXETIL | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1997-04-29 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2019-12-13 00:20 UTC | 2019-12 | N050672-001 | CEFTIN | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1994-06-30 | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N050672-002 | CEFTIN | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1997-04-29 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | N050672-001 | CEFTIN | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1994-06-30 | bb7c543d1eb4… | |
| 2022-03-09 01:35 UTC | 2022-03 | N050672-002 | CEFTIN | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1997-04-29 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | N050672-001 | CEFTIN | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1994-06-30 | 782e0a99824c… | |
| 2021-12-28 21:50 UTC | 2021-12 | N050672-002 | CEFTIN | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1997-04-29 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N050672-001 | CEFTIN | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1994-06-30 | 87673890dc5c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N050672-002 | CEFTIN | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1997-04-29 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | N050672-001 | CEFTIN | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1994-06-30 | 5aa47cf7b7d7… | |
| 2021-03-12 10:30 UTC | 2021-03 | N050672-002 | CEFTIN | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1997-04-29 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | N050672-001 | CEFTIN | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1994-06-30 | 8869cabd3fbd… | |
| 2020-12-22 03:56 UTC | 2020-12 | N050672-002 | CEFTIN | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1997-04-29 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | N050672-001 | CEFTIN | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1994-06-30 | c0c555d07b60… | |
| 2020-11-12 02:37 UTC | 2020-11 | N050672-002 | CEFTIN | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1997-04-29 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | N050672-001 | CEFTIN | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1994-06-30 | 3f01610625f2… | |
| 2019-12-14 00:12 UTC | 2019-12 | N050672-002 | CEFTIN | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1997-04-29 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | N050672-001 | CEFTIN | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1994-06-30 | b00525d2431f… | |
| 2019-09-15 20:21 UTC | 2019-09 | N050672-002 | CEFTIN | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1997-04-29 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | N050672-001 | CEFTIN | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1994-06-30 | ea99ee380514… | |
| 2019-07-19 19:46 UTC | 2019-07 | N050672-002 | CEFTIN | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1997-04-29 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N050672-001 | CEFTIN | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1994-06-30 | 6a51e52b5d6a… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N050672-002 | CEFTIN | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1997-04-29 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | N050672-001 | CEFTIN | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1994-06-30 | 1c564ffb4f44… | |
| 2024-02-18 07:12 UTC | 2024-02 | N050672-002 | CEFTIN | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1997-04-29 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | N050672-001 | CEFTIN | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1994-06-30 | ea1830bbd6c7… | |
| 2023-12-20 04:57 UTC | 2023-12 | N050672-002 | CEFTIN | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1997-04-29 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N050672-001 | CEFTIN | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1994-06-30 | a72a2bbeb626… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N050672-002 | CEFTIN | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1997-04-29 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N050672-001 | CEFTIN | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1994-06-30 | 9b2671bbb829… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N050672-002 | CEFTIN | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1997-04-29 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N050672-001 | CEFTIN | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1994-06-30 | a67488948f0b… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N050672-002 | CEFTIN | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1997-04-29 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N050672-001 | CEFTIN | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1994-06-30 | 3f0d92c62455… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N050672-002 | CEFTIN | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1997-04-29 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | N050672-001 | CEFTIN | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1994-06-30 | 053a50430f4f… | |
| 2023-05-13 08:27 UTC | 2023-05 | N050672-002 | CEFTIN | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1997-04-29 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | N050672-001 | CEFTIN | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1994-06-30 | 3bdfa0b2c4d7… | |
| 2023-01-26 05:58 UTC | 2023-01 | N050672-002 | CEFTIN | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1997-04-29 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N050672-001 | CEFTIN | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1994-06-30 | 3a93d1ddd44b… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N050672-002 | CEFTIN | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | RLD | 1997-04-29 | 3a93d1ddd44b… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Cefuroxime Axetil | CEFUROXIME AXETIL | REMEDYREPACK INC. | 76cec54f-d167-4298-951b-5411a3c47f4a | 2026-08-05 | Warnings, Adverse reactions | CEFUROXIME AXETIL |
| Cefuroxime Axetil | CEFUROXIME AXETIL | Redpharm Drug | 56cb6f42-9ae1-38e7-e063-6294a90a3feb | 2026-07-31 | Warnings, Adverse reactions | CEFUROXIME AXETIL |
| Cefuroxime Axetil | CEFUROXIME AXETIL | A-S Medication Solutions | 85cdd8d9-557e-4d15-855a-027e7809cf64 | 2026-05-14 | Warnings, Adverse reactions | CEFUROXIME AXETIL |
| Cefuroxime Axetil | CEFUROXIME AXETIL | A-S Medication Solutions | d14d4184-3e29-43cd-8046-658699c70f03 | 2026-05-14 | Warnings, Adverse reactions | CEFUROXIME AXETIL |
| Cefuroxime axetil | CEFUROXIME AXETIL | Golden State Medical Supply, Inc. | bb7955fe-5111-1662-e053-2a95a90a85a1 | 2026-04-23 | Warnings, Adverse reactions | CEFUROXIME AXETIL |
| Cefuroxime axetil | CEFUROXIME AXETIL | NuCare Pharmaceuticals, Inc. | 4e4426a4-0ca9-dad5-e063-6294a90a5fdb | 2026-03-30 | Warnings, Adverse reactions | CEFUROXIME AXETIL |
| Cefuroxime Axetil | CEFUROXIME AXETIL | PD-Rx Pharmaceuticals, Inc. | a84ac4ed-c268-4e9f-9df8-256e0a64cd16 | 2026-03-18 | Warnings, Adverse reactions | CEFUROXIME AXETIL |
| Cefuroxime Axetil | CEFUROXIME AXETIL | A-S Medication Solutions | a940ba01-2b53-4947-9019-d3d8f4e9ad80 | 2026-01-23 | Warnings, Adverse reactions | CEFUROXIME AXETIL |
| Cefuroxime axetil | CEFUROXIME AXETIL | Advanced Rx of Tennessee, LLC | 48d96608-d3da-b512-e063-6294a90a07d5 | 2026-01-16 | Warnings, Adverse reactions | CEFUROXIME AXETIL |
| Cefuroxime axetil | CEFUROXIME AXETIL | Redpharm Drug | 3744f28c-c7e1-259c-e063-6294a90a10ed | 2025-12-11 | Warnings, Adverse reactions | CEFUROXIME AXETIL |
| Cefuroxime axetil | CEFUROXIME AXETIL | PD-Rx Pharmaceuticals, Inc. | 2af8f061-c0e1-3a1c-e054-00144ff8d46c | 2025-10-15 | Warnings, Adverse reactions | CEFUROXIME AXETIL |
| Cefuroxime axetil | CEFUROXIME AXETIL | PD-Rx Pharmaceuticals, Inc. | 2af94304-8118-41c7-e054-00144ff8d46c | 2025-10-15 | Warnings, Adverse reactions | CEFUROXIME AXETIL |
| Cefuroxime Axetil | CEFUROXIME AXETIL | A-S Medication Solutions | aa6685c1-51ed-466a-ae7f-89a82986a7b1 | 2025-10-08 | Warnings, Adverse reactions | CEFUROXIME AXETIL |
| Cefuroxime Axetil | CEFUROXIME AXETIL | A-S Medication Solutions | 119c4d09-2324-498f-9318-1f8db49ad4b6 | 2025-10-08 | Warnings, Adverse reactions | CEFUROXIME AXETIL |
| Cefuroxime axetil | CEFUROXIME AXETIL | Ascend Laboratories, LLC | dd11e4b9-7730-4d3a-81ca-16f15de09759 | 2025-10-03 | Warnings, Adverse reactions | CEFUROXIME AXETIL |
| Cefuroxime Axetil | CEFUROXIME AXETIL | NuCare Pharmaceuticals, Inc. | 3f92c452-18b4-5af8-e063-6394a90aaa53 | 2025-09-24 | Warnings, Adverse reactions | CEFUROXIME AXETIL |
| Cefuroxime axetil | CEFUROXIME AXETIL | Major Pharmaceuticals | 44e1fb4d-4b61-40da-9974-0bd2006eb828 | 2025-09-12 | Warnings, Adverse reactions | CEFUROXIME AXETIL |
| Cefuroxime axetil | CEFUROXIME AXETIL | American Health Packaging | f38418a7-dd90-4f20-b747-7ac086c53015 | 2025-08-06 | Warnings, Adverse reactions | CEFUROXIME AXETIL |
| Cefuroxime Axetil | CEFUROXIME AXETIL | Preferred Pharmaceuticals Inc. | bc9200d2-4a6d-4847-ba85-8e9d378390de | 2025-07-31 | Warnings, Adverse reactions | CEFUROXIME AXETIL |
| Cefuroxime axetil | CEFUROXIME AXETIL | PD-Rx Pharmaceuticals, Inc. | 15cabe73-f39d-4798-a840-115fe94f8f96 | 2025-03-13 | Warnings, Adverse reactions | CEFUROXIME AXETIL |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Documents#
| Document | Submission type | Date |
|---|---|---|
| 66687 | SUPPL | 2021-03-09 |
| 66663 | SUPPL | 2021-03-09 |
| 58435 | SUPPL | 2019-04-26 |
| 50085 | SUPPL | 2017-10-18 |
| 50072 | SUPPL | 2017-10-17 |
| 45976 | SUPPL | 2016-12-01 |
| 45951 | SUPPL | 2016-11-23 |
| 30257 | SUPPL | 2015-08-28 |
| 18002 | SUPPL | 2015-08-27 |
| 30256 | SUPPL | 2015-07-07 |
| 39091 | SUPPL | 2015-07-01 |
| 30255 | SUPPL | 2014-09-23 |
| 30254 | SUPPL | 2014-09-23 |
| 39090 | SUPPL | 2014-09-22 |
| 39089 | SUPPL | 2014-09-22 |
| 39088 | SUPPL | 2007-08-02 |
| 7968 | SUPPL | 2007-08-02 |
| 39087 | SUPPL | 2004-06-07 |
| 30253 | SUPPL | 2004-06-07 |
| 30252 | SUPPL | 2002-04-11 |
| 18001 | SUPPL | 2002-04-11 |
| 18000 | SUPPL | 2002-03-29 |
| 7967 | SUPPL | 2002-03-29 |
| 30251 | SUPPL | 1999-08-24 |
| 22176 | SUPPL | 1999-08-24 |